ロード中...
Cost-Effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema: Analysis from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial
IMPORTANCE: Anti-vascular endothelial growth factor (anti-VEGF) medicines have revolutionized diabetic macular edema (DME) treatment. A recent randomized clinical trial comparing anti-VEGF agents for patients with decreased vision from DME found that at one year aflibercept (2.0-mg) achieved better...
保存先:
| 出版年: | JAMA Ophthalmol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6648661/ https://ncbi.nlm.nih.gov/pubmed/27280850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2016.1669 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|